Novacyt

Novacyt Revenue per Share

The Revenue per Share of Novacyt (ALNOV.PA) as of Oct 18, 2026 is 0.29 GBP. In the previous year, Revenue per Share was 0.28 GBP — a change of 3.94% (higher).

Revenue per Share

0.29GBP

YoY

3.94%

Last updated:

Revenue per Share of Novacyt is 2025 0.29 GBP. Revenue per Share of Novacyt was 2024 0.28 GBP. It decreases by 3.94% higher compared to the previous year.

The Novacyt Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2020
3.92 GBP
Jan 1, 2021
1.31 GBP
Jan 1, 2022
0.30 GBP
Jan 1, 2023
0.16 GBP
Jan 1, 2024
0.28 GBP
Jan 1, 2025
0.29 GBP
Jan 1, 2026 (e)
0.43 GBP
Jan 1, 2027 (e)
0.49 GBP
The Novacyt Revenue per Share history
YEARRevenue per ShareYoY
est0.49GBP+14.20%
est0.43GBP+49.60%
0.29GBP+3.94%
0.28GBP+69.53%
0.16GBP-44.97%
0.30GBP-77.28%
1.31GBP-66.59%
3.92GBP+1,692.54%
0.22GBP-28.88%
0.31GBP-28.94%
0.43GBP-37.35%
0.69GBP-34.33%
1.05GBP-11.46%
1.19GBP+238.65%
0.35GBP+18.90%
0.30GBP+3,186.98%
0.01GBP-39.82%
0.01GBP+23.49%
0.01GBP+102.05%
0.01GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Revenue per Share of Novacyt is 0.29 GBP in 2025.

Revenue per Share of Novacyt changed from 0.28 GBP to 0.29 GBP, representing a 3.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Novacyt since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Novacyt

All Key Metrics — Novacyt